Table 1 Biodemographic and clinical characteristics of patients and controls
Characteristics | CML patients | Controls (n = 20) | |
|---|---|---|---|
TKI (n = 33) | TKI + IFN-α (n = 8) | ||
Demographic features | |||
Gender (%) | |||
Male | 18 (54.5) | 4 (50.0) | 7 (35.0) |
Female | 15 (45.5) | 4 (50.0) | 13 (65.0) |
Age (years) | |||
Median | 63 | 50 | 58 |
Range | 37–84 | 34–62 | 30–89 |
Clinical features | |||
Age at diagnosis (years) | |||
Median | 50 | 42 | |
Range | 24–78 | 25–60 | |
Time of disease (years) | |||
Median | 11.2 | 3.4 | |
Range | 1.3–22.7 | 2.1–24.1 | |
Scoring systems | |||
Sokal score | (n = 32) | (n = 7) | |
Low risk (%) | 13 (40.6) | 4 (57.1) | |
Intermediate risk (%) | 13 (40.6) | 1 (14.3) | |
High risk (%) | 6 (18.8) | 2 (28.6) | |
Euro score | (n = 32) | (n = 7) | |
Low risk (%) | 14 (43.8) | 5 (71.4) | |
Intermediate risk (%) | 17 (53.2) | 2 (28.6) | |
High risk (%) | 1 (3.0) | – | |
Eutos score | (n = 33) | (n = 7) | |
Low risk (%) | 27 (81.8) | 1 (14.3) | |
High risk (%) | 6 (18.2) | 6 (85.7) | |
Type of TKI | |||
Imatinib (%) | 26 (78.8) | 6 (75.0) | |
Nilotinib (%) | 1 (3.0) | 2 (25.0) | |
Dasatinib (%) | 2 (6.1) | – | |
Bosutinib (%) | 3 (9.1) | – | |
Ponatinib (%) | 1 (3.0) | – | |